drugset / Trial / NCT06454357
A Clinical Study of B007 in the Treatment of Pemphigus.
Phase 2/3
Recruiting
132 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
Timeline
- Start
- 2024-07-12
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B007 | Monoclonal antibody | — | Subcutaneous |